Telomeric DNA: Marker for human prostate cancer development?

Prostate

Volumn 36, Issue 4, 1998, Pages 264-271

  Ozen, Mustafa ^a,b   Imam, S Ashraf ^c   Datar, Ram H ^c   Multani, Asha S ^a   Narayanan, Ram ^d   Chung, Leland W K ^e   Von Eschenbach, Andrew C ^a   Pathak, Sen ^a,b,f  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Programmed cell death; Prostate cancer; Ribonucleoprotein; Telomerase; Telomere; TRAP assay

Indexed keywords

DNA; TELOMERASE;

APOPTOSIS; ARTICLE; CELL TRANSFORMATION; DNA DETERMINATION; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SOMATIC CELL; TELOMERE;

APOPTOSIS; BASE SEQUENCE; CELLS, CULTURED; DNA PRIMERS; DNA RESTRICTION ENZYMES; DNA, NEOPLASM; FIBROBLASTS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PROSTATE; PROSTATIC NEOPLASMS; TELOMERASE; TELOMERE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0031810956     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980901)36:4<264::AID-PROS8>3.0.CO;2-F     Document Type: Article

References (25)

1. Moyzis RK, Buckingham J, Cram LS, Dani M, Deaven LL, Jones MD, Meyne J, Ratliff RL, Wu JR: A highly conserved repetitive DNA sequence (TTAGGG)n present at the telomeres of human chromosomes. Proc Natl Acad Sci USA 1988;85:6622-6626.
2. Harley CB: Telomere loss: Mitotic clock or genetic time bomb? Mutat Res 1991;256:271-282.
3. Ozen M, Multani AS, Chang S, von Eschenbach AC, Chung LWK, Pathak S: Establishment of an in vitro cell model system to study human prostate carcinogenesis: Involvement of chromosome 5 in early stages of neoplastic transformation. Int J Oncol 1996;8:883-888.
4. Pathak S, Wang Z, Dhaliwal MK, Sacks PL: Telomeric associations: Another characteristic of cancer chromosomes? Cytogenet Cell Genet 1988;47:227-229.
5. Pathak S, Risin S, Brown NM, Berry K: Telomeric association of chromosomes is an early manifestation of programmed cell death. Int J Oncol 1994;4:323-328.
6. Pathak S, Dave BJ, Gagos S: Chromosome alterations in cancer development and apoptosis. In Vivo 1994;8:843-850.
7. Pathak S, Multani AS, Amoss MS: Telomere, telomerase, and malignant melanomas in human and domestic mammals. Arch Zootec 1996;45:141-149.
8. Holzmann K, Blin N, Welter C, Zang KD, Seitz G, Henn W: Telomeric associations and loss of telomeric DNA repeats in renal tumors. Genes Chromosomes Cancer 1993;6:178-181.
9. Saltman D, Morgan R, Cleary ML, de Lange T: Telomeric structure in cells with chromosome end associations. Chromosoma 1993;102:121-128.
10. Schmitt H, Blin N, Zankl H, Schertnan H: Telomere length variation in normal and malignant human tissues. Genes Chromosomes Cancer 1994;11:171-177.
11. Pathak S: Chromosome banding techniques. J Reprod Med 1976; 17:25-28.
12. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
13. de Lange T, Shiue L, Myers RM, Cox DR, Naylor SL, Killary AM, Varmus HE: Structure and variability of human chromosome ends. Mol Cell Biol 1990;10:518-527.
14. Danesi R, Figg WD, Reed E, Myers CM: Paclitaxel (Taxol) inhibits protein isopyrenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol 1995;47:1106-1111.
15. Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E: Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 1995; 55:2122-2128.
16. Li CJ, Wang C, Pardee AB: Induction of apoptosis by β-lapachone in human prostate cancer cells. Cancer Res 1995;55: 3712-3715.
17. Denmeade SR, Lin XS, Isaacs JT: Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;26:251-265.
18. Kyprianou N, Bains AK, Jacobs SC: Induction of apoptosis in androgen-independent prostate cancer cells undergoing thymineless death. Prostate 1994;25:66-75.
19. Hockenbery D, Nunez G, Millman C, Schreiber RD, Korsemeyer SJ: bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
20. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
21. Yoshida K, Kadmon D, Truong LD, Aihara M, Park SH, Timme TL, Scardino PT, Thompson TC: Association of apoptosis related genes with the development of oncogene-induced prostate cancer in the mouse prostate reconstitution model system (abstract 1027). J Urol 1993;149:469.
22. Wheeler TM, Rogers E, Aihara M, Scardino PT, Thompson TC: Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer. J Cell Biochem 1994;19:202-207.
23. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC: Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 1994; 25:797-801.
24. Pandita TK, Pathak S, Geard CR: Chromosome end associations, telomeres and telomerase activity in ataxia telangiectasia cells. Cytogenet Cell Genet 1995;71:86-93.
25. Lin Y, Uemura H, Fujinami K, Hosaka M, Harada M, Kubota Y: Telomerase activity in primary prostate cancer. J Urol 1997;157: 1161-1165.